The proof-of-concept studies here are consistent with a mechanism of action wherein REDD1 suppression improves visual acuity in diabetic patient by preventing sustained NF-κB activation and reducing the retinal inflammatory response to diabetes. The gene discussed is NFKB1; the disease is diabetes mellitus.